Aghapour Zahra, Gholizadeh Pourya, Ganbarov Khudaverdi, Bialvaei Abed Zahedi, Mahmood Suhad Saad, Tanomand Asghar, Yousefi Mehdi, Asgharzadeh Mohammad, Yousefi Bahman, Kafil Hossein Samadi
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Infect Drug Resist. 2019 Apr 24;12:965-975. doi: 10.2147/IDR.S199844. eCollection 2019.
Colistin is an effective antibiotic for treatment of most multidrug-resistant Gram-negative bacteria. It is used currently as a last-line drug for infections due to severe Gram-negative bacteria followed by an increase in resistance among Gram-negative bacteria. Colistin resistance is considered a serious problem, due to a lack of alternative antibiotics. Some bacteria, including , , Enterobacteriaceae members, such as spp., and spp. have an acquired resistance against colistin. However, other bacteria, including spp., spp. and spp. are naturally resistant to this antibiotic. In addition, clinicians should be alert to the possibility of colistin resistance among multidrug-resistant bacteria and development through mutation or adaptation mechanisms. Rapidly emerging bacterial resistance has made it harder for us to rely completely on the discovery of new antibiotics; therefore, we need to have logical approaches to use old antibiotics, such as colistin. This review presents current knowledge about the different mechanisms of colistin resistance.
黏菌素是治疗大多数耐多药革兰氏阴性菌的有效抗生素。目前它被用作治疗由严重革兰氏阴性菌引起感染的最后一线药物,随后革兰氏阴性菌中的耐药性有所增加。由于缺乏替代抗生素,黏菌素耐药性被认为是一个严重问题。一些细菌,包括 、 、肠杆菌科成员,如 属和 属,已获得对黏菌素的耐药性。然而,其他细菌,包括 属、 属和 属,对这种抗生素天然耐药。此外,临床医生应警惕耐多药细菌中黏菌素耐药性通过突变或适应机制产生和发展的可能性。迅速出现的细菌耐药性使我们更难以完全依赖新抗生素的发现;因此,我们需要有合理的方法来使用旧抗生素,如黏菌素。本综述介绍了关于黏菌素耐药性不同机制的当前知识。